ArriVent BioPharma, Inc. (AVBP)
(Real Time Quote from BATS)
$17.71 USD
+0.76 (4.48%)
Updated Aug 13, 2025 10:42 AM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AVBP 17.71 +0.76(4.48%)
Will AVBP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AVBP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AVBP
New Strong Sell Stocks for July 21st
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 27.26%: Read This Before Placing a Bet
AVBP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's What Could Help ArriVent BioPharma, Inc. (AVBP) Maintain Its Recent Price Strength
Other News for AVBP
HC Wainwright & Co. Raises Price Target for AVBP to $42 | AVBP Stock News
Citigroup Lowers Price Target for ArriVent BioPharma (AVBP) while Maintaining 'Buy' Rating | ...
ArriVent Biopharma price target raised by $2 at H.C. Wainwright, here's why
ArriVent Biopharma price target lowered by $7 at Citi, here's why
ArriVent BioPharma Reports Second Quarter 2025 Financial Results | AVBP Stock News